Vaccines and Value Assessment – 7 Updates

Navigating the evaluation requirements from health technology assessment (HTA) agencies and national immunization technical agency groups (NITAGs) is a must for vaccine development. PRMA Consulting has released a series of 7 articles meant to bring health outcomes and economics researchers and market access teams up to speed on these requirements and shine a light on the stakeholders involved in the evaluation process. In addition, these articles will aid in preparing global value dossiers and more.

According to PRMA Consulting, one article will help readers, “Learn why a quality-adjusted life-year (QALY) is a recommended measure of benefit in the economic evaluation of vaccines, and discover more about health benefits and the discounting of costs in vaccine economic models across markets.”

Find links to all seven articles by clicking here.

(Source: PMRA Consulting, December 8^th, 2021)